Novartis Bets Big on Alzheimer’s with $1.7 B Licensing Deal with SciNeuro Pharmaceuticals
Novartis has entered into a licensing and collaboration agreement with SciNeuro Pharmaceuticals for the development of therapies targeting Alzheimer’s disease, […]
